Covance & Sanofi ink 10-year, $2.2bn strategic R&D alliance

By Nick Taylor

- Last updated on GMT

Related tags Covance Sanofi-aventis

Covance has inked a 10-year strategic alliance, worth up to $2.2bn, with Sanofi-Aventis and acquired two European sites from the big pharma.

Inking the deal makes Covance Sanofi’s research and development partner. Covance has also acquired Sanofi sites in Porcheville, France and Alnwick, UK for $25m and will maintain employment at these facilities for at least the next five years.

Covance will provide Sanofi with discovery support, toxicology, chemistry, Phase I to IV, central lab and market access services. The deal includes a 10-year sole-source relationship for central lab services. Covance currently performs less than 50 per cent of Sanofi’s central lab work.

An initial $1.2bn will be added to Covance’s backlog in the third quarter. The remaining revenues are accounted for by central lab work and other long-term commitments. Of the service proportion of the deal, 75 per cent of revenue is for late stage work such as central lab and Phase III.

Outsourcing at Sanofi

In a call with investors Herring said Sanofi was a relatively small client, generating revenues of $35m in 2009, most of which was for central lab work. Herring said revenues from Sanofi will ramp up in the next few years but no clients will contribute more than 10 per cent of total sales.

Sanofi has traditionally outsourced relatively little, said Herring, but this has changed as Chris Viehbacher, CEO at the big pharma, has sought to restructure research and development operations.

Part of this effort is shifting away from using a large number of CROs. Herring said biopharm is discovering savings made negotiating outsourcing deals individually are negated by the overheads and complexity created by managing relationships with many different CROs.

The sites

In a conference call with investors Herring said both sites have been well maintained and require little investment, other than $12-15m to implement Covance’s IT system. Maintenance costs are the only other expected infrastructure outlay.

Covance believes the acquired assets can be commercialised and will begin defining its strategy once it has dealt with administrative tasks at each site. Herring said “to some degree there is pent up demand​” for the chemistry, manufacturing and control (CMC) capacity the sites give Covance.

Birth of the deal

A small team of senior Sanofi executives visited Covance in February to open a dialogue. In the autumn of 2009 the sites in Porcheville and Alnwick were discussed as Covance and Sanofi sought to establish how they could help each other.

The structure of the deal was created over a few months and a memorandum of understanding signed in spring 2010. More than 100 Covance employees have been working on the transaction.

Related news

Show more

Related products

show more

Unlock potential in buffer preparation

Unlock potential in buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 18-Sep-2023 | Infographic

Consider how the right partner can help you scale faster, mitigate risks, and optimize resources.

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 14-Aug-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Automated metadata management in clinical trials

Automated metadata management in clinical trials

Content provided by Formedix | 01-Aug-2023 | White Paper

When it comes to efficient clinical study build, content is king. Most importantly: metadata content. In this blog, we explore the role of metadata in...

Small Molecule development – getting it right

Small Molecule development – getting it right

Content provided by Lonza Small Molecules | 20-Jun-2023 | Insight Guide

Small Molecule drug development is something more and more ambitious emerging pharmaceutical companies are taking on from end to end. But this path can...

Related suppliers

Follow us


View more